Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients
New predictors of ischemic incidents are constantly sought since they raise the awareness of patients and their doctors of stroke occurrence. The goal was to verify whether Advanced Glycation End Products (AGEs), in particular AGE10, could be one of them. The AGE10 measurement was conducted using a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/2/443 |
| _version_ | 1797339688545026048 |
|---|---|
| author | Aleksandra Kuzan Anna Kozak-Sykała Anna Fiedorowicz Wojciech Kałas Leon Strządała Andrzej Gamian |
| author_facet | Aleksandra Kuzan Anna Kozak-Sykała Anna Fiedorowicz Wojciech Kałas Leon Strządała Andrzej Gamian |
| author_sort | Aleksandra Kuzan |
| collection | DOAJ |
| description | New predictors of ischemic incidents are constantly sought since they raise the awareness of patients and their doctors of stroke occurrence. The goal was to verify whether Advanced Glycation End Products (AGEs), in particular AGE10, could be one of them. The AGE10 measurement was conducted using a non-commercial ELISA assay in the blood serum of neurological patients without cerebrovascular event (n = 24), those with transient brain attack (TIA) (n = 17), and severe ischemic stroke (n = 35). Twice as many of the people with TIA or severe stroke presented high AGE10 serum concentrations compared to the patients with other neurological conditions (χ<sup>2</sup> = 8.2, <i>p</i> = 0.004; χ<sup>2</sup> = 8.0, <i>p</i> = 0.005, respectively). The risk of ischemic incident was significantly risen in people with higher levels of AGE10 (OR = 6.5, CI95%: 1.7–24.8; OR = 4.7, CI95%: 1.5–14.5 for TIA and stroke subjects, respectively). We observed a positive correlation (r = 0.40) between high AGE10 levels and diabetes. Moreover, all the diabetic patients that had a high AGE10 content experienced either a severe ischemic stroke or TIA. The patients with high levels of AGE10 exhibited higher grades of disability assessed by the NIHSS scale (r = 0.35). AGE10 can be considered a new biomarker of ischemic stroke risk. Patients with diabetes presenting high AGE10 levels are particularly prone to the occurrence of cerebrovascular incidents. |
| first_indexed | 2024-03-08T09:52:01Z |
| format | Article |
| id | doaj.art-855d912f70df491d97c9077c4f9e53ee |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T09:52:01Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-855d912f70df491d97c9077c4f9e53ee2024-01-29T14:01:49ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113244310.3390/jcm13020443Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic PatientsAleksandra Kuzan0Anna Kozak-Sykała1Anna Fiedorowicz2Wojciech Kałas3Leon Strządała4Andrzej Gamian5Department of Biochemistry and Immunochemistry, Wroclaw Medical University, 50-367 Wroclaw, PolandNeurology and Stroke Department, Independent Public Healthcare Centre, Jankowski Regional Hospital in Przeworsk, Szpitalna 16, 37-200 Przeworsk, PolandHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandNew predictors of ischemic incidents are constantly sought since they raise the awareness of patients and their doctors of stroke occurrence. The goal was to verify whether Advanced Glycation End Products (AGEs), in particular AGE10, could be one of them. The AGE10 measurement was conducted using a non-commercial ELISA assay in the blood serum of neurological patients without cerebrovascular event (n = 24), those with transient brain attack (TIA) (n = 17), and severe ischemic stroke (n = 35). Twice as many of the people with TIA or severe stroke presented high AGE10 serum concentrations compared to the patients with other neurological conditions (χ<sup>2</sup> = 8.2, <i>p</i> = 0.004; χ<sup>2</sup> = 8.0, <i>p</i> = 0.005, respectively). The risk of ischemic incident was significantly risen in people with higher levels of AGE10 (OR = 6.5, CI95%: 1.7–24.8; OR = 4.7, CI95%: 1.5–14.5 for TIA and stroke subjects, respectively). We observed a positive correlation (r = 0.40) between high AGE10 levels and diabetes. Moreover, all the diabetic patients that had a high AGE10 content experienced either a severe ischemic stroke or TIA. The patients with high levels of AGE10 exhibited higher grades of disability assessed by the NIHSS scale (r = 0.35). AGE10 can be considered a new biomarker of ischemic stroke risk. Patients with diabetes presenting high AGE10 levels are particularly prone to the occurrence of cerebrovascular incidents.https://www.mdpi.com/2077-0383/13/2/443advanced glycation end-productsischemic stroketransient brain attackdiabetesvascular complicationscerebrovascular diseases |
| spellingShingle | Aleksandra Kuzan Anna Kozak-Sykała Anna Fiedorowicz Wojciech Kałas Leon Strządała Andrzej Gamian Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients Journal of Clinical Medicine advanced glycation end-products ischemic stroke transient brain attack diabetes vascular complications cerebrovascular diseases |
| title | Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients |
| title_full | Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients |
| title_fullStr | Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients |
| title_full_unstemmed | Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients |
| title_short | Advanced Glycation End-Products in Blood Serum—Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients |
| title_sort | advanced glycation end products in blood serum novel ischemic stroke risk factors implication for diabetic patients |
| topic | advanced glycation end-products ischemic stroke transient brain attack diabetes vascular complications cerebrovascular diseases |
| url | https://www.mdpi.com/2077-0383/13/2/443 |
| work_keys_str_mv | AT aleksandrakuzan advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients AT annakozaksykała advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients AT annafiedorowicz advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients AT wojciechkałas advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients AT leonstrzadała advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients AT andrzejgamian advancedglycationendproductsinbloodserumnovelischemicstrokeriskfactorsimplicationfordiabeticpatients |